

Telmisartan Market Surges Amid Rising Hypertension Rates and Expanding Generic Approvals: Key Drivers and Opportunities

Global Telmisartan Market Set for Growth: Aging Population, Generic Drug Expansion, and Online Pharmacies Fuel Demand

PORTLAND, OR, UNITED STATES, September 27, 2024 / EINPresswire.com/ -- The global <u>telmisartan market</u>, valued at \$3,453 million in 2019, is expected to reach \$4,258 million by 2027, growing at a compound annual growth rate (CAGR) of 3.4% from 2020 to 2027.



Telmisartan Market size, share, demand, forecast

Telmisartan, a non-peptide angiotensin

receptor blocker (ARB), is primarily used to treat hypertension and reduce cardiovascular risk.

000 0 00000 0000 00 0000 000000: <u>https://www.alliedmarketresearch.com/request-</u> sample/A10293

٢

Emerging economies, particularly in the Asia-Pacific region, are likely to be the focus of future expansion efforts, offering a lucrative opportunity for pharmaceutical companies" *Allied Market Research* Here's a detailed analysis of the market dynamics:

Key Market Drivers

• Rising Prevalence of Hypertension: Increasing rates of high blood pressure, especially among the aging population, are driving demand for telmisartan.

• Growing Geriatric Population: As the global population ages, cardiovascular diseases and hypertension are becoming more common, boosting the telmisartan market.

- Government Initiatives: Campaigns like 'May Measurement Month & World Hypertension Day' raise awareness of hypertension, contributing to market growth.
- Approval of Generic Versions: The introduction of generic telmisartan versions has made the

drug more accessible and affordable, further boosting market expansion.

Market Challenges

• Drug Shortages: Occasional shortages in the availability of telmisartan could restrain market growth.

• Side Effects: Common side effects, such as dizziness and lightheadedness, may limit the drug's use among sensitive patient groups.

Market Opportunities

• Emerging Economies: Growing research and development in developing countries offer significant growth opportunities for telmisartan.

• Increased Online Pharmacies: The rise of e-pharmacies provides convenient access to telmisartan, especially in remote regions.

Segmentation Insights

• By Indication:

• Hypertension: This segment is the largest contributor to market revenue, driven by the growing demand for antihypertensive medications.

• Cardiovascular Risk Reduction: Telmisartan is also widely used to reduce cardiovascular complications, especially among high-risk patients.

• By Distribution Channel:

• Hospital Pharmacies: The dominant distribution channel, benefiting from the large number of hospitalized hypertension patients.

• Online Pharmacies: Expected to grow rapidly due to increased online drug purchasing, convenience, and price comparison options.

Regional Analysis

• Asia-Pacific: This region offers significant growth potential due to the rising number of hypertension cases, government support for health reforms, and increasing awareness of cardiovascular diseases.

• North America & Europe: Established markets with high rates of hypertension, though growth is moderate due to market maturity.

Competitive Landscape

Key players in the telmisartan market include:

- Abbott Laboratories
- Aurobindo Pharma
- Boehringer Ingelheim
- Cipla Inc.
- Glaxosmithkline Plc (GSK)
- Mylan N.V.
- Sanofi

- Sun Pharmaceutical Industries Limited
- Teva Pharmaceutical Industries Ltd.
- Zydus Cadila

David Correa Allied Market Research +1 800-792-5285 email us here Visit us on social media: Facebook X

This press release can be viewed online at: https://www.einpresswire.com/article/747054823

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information. © 1995-2024 Newsmatics Inc. All Right Reserved.